NCT04973033 is a NA clinical trial of Tofacitinib in ANCA Associated Vasculitis, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT04973033?

NCT04973033 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT04973033?

Interventions in NCT04973033: Tofacitinib.

What condition does NCT04973033 study?

NCT04973033 studies ANCA Associated Vasculitis, Drug Use, JAK-STAT Pathway Deregulation.

Is NCT04973033 still recruiting?

NCT04973033 is currently completed. Last updated 22 July 2021.

Last reviewed 2021-07-22 · How we verify

NCT04973033

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Tofacitinib in Treating ANCA-associated Vasculitis

Completed NA Last updated 22 July 2021

What this trial tests

NA trial testing Tofacitinib in ANCA Associated Vasculitis in 10 participants. Completed in 31 January 2021.

Timeline

1 December 2019

Primary endpoint
31 January 2021

31 January 2021

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 December 2019
Primary completion	31 January 2021
Estimated completion	31 January 2021
Sites	1 location across China

Drugs / interventions tested

Tofacitinib (tofacitinib) — full drug profile →

Conditions studied

ANCA Associated Vasculitis — all drugs for ANCA Associated Vasculitis →
Drug Use — all drugs for Drug Use →
JAK-STAT Pathway Deregulation — all drugs for JAK-STAT Pathway Deregulation →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 75, any sex, with ANCA Associated Vasculitis or Drug Use. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to evaluate the efficacy and safety of tofacitinib 5 mg twice daily in AAV patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies.
Molnár A, Studinger P, Ledó N. · · 2022 · cited 16× · PMID 35721093 · DOI 10.3389/fmed.2022.884188
A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis.
Casal Moura M, Branco C, Martins-Martinho J, Ferraro JL, et al · · 2022 · cited 8× · PMID 36353270 · DOI 10.1177/1759720x221125979

Verify or expand the search:

Other trials of Tofacitinib

Trials testing the same drug.

NCT07530367 — A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Pati · Phase 3 · not yet recruiting
NCT07406204 — Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) · Phase 4 · not yet recruiting
NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined · NA · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT07297069 — Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial · Phase 2 · not yet recruiting

Other recruiting trials for ANCA Associated Vasculitis

Currently open trials in the same condition.

NCT07203404 — A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. · EARLY_PHASE1 · recruiting
NCT06548607 — Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT06508346 — Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV · recruiting
NCT06373081 — Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease · NA · recruiting
NCT06277427 — Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells · NA · recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04973033 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 22 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04973033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing